CIMO 1. Investigación clínica y traslacional en Cáncer
Lineas de Investigación
01. Investigación clínica-traslacional en cáncer de mama, pulmón, digestivo y oncohematológico.
02. Investigación traslacional en identificación de marcadores epigenéticos/genético de fases tempranas de cáncer.
03. Investigación en el uso de nuevas técnicas de diagnóstico (biopsia líquida…) y marcadores.
Miembros del grupo
- Todos
- IR
- Co-IR
- Investigador
- Tecnico Laboratorio
- Otro
Proyectos de Investigación
Characterisation of the molecular subtypes defined by PAM50 and evaluation of the basal phenotypes in patients with breast, endometrial and bladder cancer
Instituto de Salud Carlos III (ISCIII)Área 2. Oncología y Hematología. A2-08-2020 Iñaki Comino y A2-05-2020 Beatriz Martínez Poveda
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPI-0291-2019. ENSAYOS MULTI-OMICOS PARA DETERMINAR EL RIESGO A RECAÍDA Y DETECTAR ENFERMEDAD MÍNIMA RESIDUAL EN PACIENTES CON CÁNCER DE MAMA TEMPRANO USANDO BIOPSIAS LÍQUIDAS
Consejería de Salud y FamiliasIJC2018-036275-I AYUDAS JUAN DE LA CIERVA – INCORPORACIÓN 2018.
Agencia Estatal de InvestigaciónCM19-00038 Contratos Río Hortega 2019
CD19-00211 Contratos Sara Borrell 2019
ISCIIIPE-0106-2019. Papel de la microbiota mamaria e intestinal en los diferentes subtipos intrínsecos de cáncer de mama y en su respuesta al tratamiento.
Consejería de Salud y Familias003-2019-IBD II PREMIO IBIMA-DIVULGA 2019 A LAS MEJORES PUBLICACIONES DE 2018
FIMABISFI19/00112 Contratos predoctorales de formación en investigación en salud
ISCIIIInfluencia de la microbiota intestinal en la toxicidad y respuesta a la radioquimioterapia preoperatoria en cancer de recto localmente avanzado
INSTITUTO DE SALUD CARLOS IIIPI18-01592 Integración de ómicas para la terapia dirigida en inmunoterapia: hacia la biopsia líquida
INSTITUTO DE SALUD CARLOS IIICPII18-00003 Miguel Servet Tipo II
INSTITUTO DE SALUD CARLOS IIIPI18-00453 Microbiota Intestinal y Regulación del Apetito en la Obesidad. Efectividad sobre Reducción Ponderal de una Dieta Mediterránea Hipocalórica o Ayuno Intermitente y de un Probiótico.
INSTITUTO DE SALUD CARLOS IIIPI15/00256 Influencia de la microbiota intestinal en la toxicidad y respuesta a la radioquimioterapia preoperatoria en pacientes con cáncer de recto localmente avanzado
INSTITUTO DE SALUD CARLOS IIICM16/00188 Contrato Río Hortega
SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICAPI18-00620 Caracterización de subtipos moleculares definidos por PAM50 y estudio del comportamiento clínico del fenotipo basal en pacientes con cáncer de mama, endometrio y vejiga.
INSTITUTO DE SALUD CARLOS IIIPI15/01823 Correlación del perfil mutacional y de expresión de la enfermedad residual y de la primera metástasis del tumor primario en mujeres con cáncer de mama tratadas en neoadyuvancia.
INSTITUTO DE SALUD CARLOS IIIEstudios Clínicos
Estudio de fase II multicéntrico, controlado con activo, aleatorizado para comparar la eficacia y seguridad de la terapia dirigida o inmunoterapia para el cáncer guiada por el perfil genómico frente a la quimioterapia basada en platino en pacientes con cá.
F. HOFFMANN-LA ROCHE LTDEnsayo Fase III, Randomizado, Doble ciego y controlado con Placebo de Durvalumab y Quimioterapia FLOT Neoadyuvante-Adyuvante seguido de Durvalumab Adyuvante en pacientes con cáncer gástrico y de la unión gastroesofágica resecable (GC/GEJC) (MATTERHORN).
ASTRAZENECA AB MMEstudio para evaluar el efecto de la metformina en la prevención de la hiperglucemia en pacientes con cáncer de mama avanzado con HR positivo/HER2 negativo y mutación en PIK3ca tratados con alpelisib y terapia endocrina. Estudio Metallica..
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR)Estudio de fase 3, aleatorizado, multicéntrico, doble ciego de SAR439859 más palbociclib en comparación con letrozol más palbociclib para el tratamiento de pacientes con cáncer de mama RE(+), HER2(-) que no han recibido ningún tratamiento antineoplásico s.
SANOFI AVENTIS RECHERCHE & DEVELOPPEMENTEstudio de fase II, aleatorizado, abierto, internacional y multicéntrico, para comparar la eficacia de la quimioterapia estándar frente a letrozol más abemaciclib como terapia neoadyuvante en pacientes con cáncer de mama con RH-positivo/HER2-negativo de r.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMEnsayo clínico exploratorio “basket” de cabozantinib más atezolizumab en neoplasias avanzadas y en progresión del sistema endocrino..
GETNE (GRUPO ESPAÑOL DE TUMORES NEUROENDOCRINOS Y ENDOCRINOS)A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastati.
ABBVIE DEUTSCHLAND GMBH & CON K. GEstudio de Fase III, aleatorizado, doble ciego y controlado con placebo de Atezolizumab con o sin Tiragolumab (Anticuerpo Anti-TIGIT) en pacinetes con cardinoma epidermoide de esófago localmente avanzado irresecable..
F. HOFFMANN-LA ROCHE LTDEstudio de fase 2a de ZW25 en combinación con palbociclib más fulvestrant.
ZYMEWORKS, INCTerapia con Neratinib dirigida a los receptores EGFR/ERBB2 en cancer de mama metastásico con receptor hormonal-positivo/HER2-negativo y HER2-enriquecido. (Ensayo NEREA).
SOLTIEstudio Fase II, aleatorizado, abierto de SAR439859 versus monoterapia endocrina a elección médica en pacientes premenopáusicas y postmenopáusicas con cáncer de mama con receptores de estrógeno positivos, HER2 negativo localmente avanzado o metastásico co.
SANOFI AVENTIS RECHERCHE & DEVELOPPEMENTENSAYO DE FASE IIa, MULTICÉNTRICO, ABIERTO, NO COMPARATIVO Y DE TRES BRAZOS DE IPATASERTIB (GDC-0068) EN COMBINACIÓN CON QUIMIOTERAPIA SIN TAXANOS PARA PACIENTES CON CÁNCER DE MAMA TRIPLE-NEGATIVO LOCALMENTE AVANZADO IRRESECABLE O METASTÁSICO PREVIAMENTE.
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR)Estudio fase 3, aleatorizado, multicéntrico, doble ciego, controlado con placebo, de nivolumab frente a placebo en combinación con quimioterapia neoadyuvante y tratamiento hormonal adyuvante en pacientes con cáncer de mama primario de alto riesgo, recepto.
BRISTOL-MYERS SQUIBB COMPANYEstudio de fase III, abierto, aleatorizado y multicéntrico de irinotecán liposómico inyectable, oxaliplatino, 5-fluorouracilo/leucovorina frente a nab-paclitaxel más gemcitabina en pacientes que no han recibido previamente quimioterapia para el adenocarci.
IPSEN BIOSCIENCE, INCEstudio fase II, aleatorizado, no comparativo, neoadyuvante, en pacientes con cáncer de mama RE+/HER2- ? 2 cm con preinclusión de seguridad, para evaluar nivolumab + palbociclib + anastrozol..
BRISTOL-MYERS SQUIBB COMPANYEstudio en fase III aleatorizado y doble ciego para evaluar la eficacia y la seguridad de capivasertib + fulvestrant frente a placebo + fulvestrant como tratamiento para el cáncer de mama localmente avanzado (inoperable) o metastásico con receptor hormona.
ASTRAZENECA AB MMEnsayo clínico fase III, multicéntrico, aleatorizado y abierto, para evaluar la eficacia y seguridad de ribociclib con terapia endocrina, como tratamiento adyuvante en pacientes con cáncer de mama precoz, receptores hormonales positivos, HER2 negativo (.
NOVARTIS FARMACEUTICA, S.A.HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302.
SOLTIEnsayo clínico de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de niraparib más inhibidores de aromatasa en el cáncer de mama metastásico con receptor hormonal (RH) positivo/receptor del factor de crecimiento epidérmico humano 2 (.
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR)ESTUDIO FASE IIIB MULTICÉNTRICO, ABIERTO, DE UN SOLO BRAZO, PARA EVALUAR LA SEGURIDAD DE ATEZOLIZUMAB (TECENTRIQ) EN COMBINACIÓN CON NAB-PACLITAXEL O PACLITAXEL PARA EL TRATAMIENTO DEL Cà NCER DE MAMA TRIPLE NEGATIVO INOPERABLE, LOCALMENTE AVANZADO O ME.
Roche Farma, S.A.Estudio abierto y multicéntrico en fase II de DS-8201a, un anti-HER2 conjugado anticuerpo-fármaco (CAF) para sujetos con cáncer de mama HER2 positivo irresecable y/o metastásico que han recibido tratamiento anteriormente con T-DM1.
Daiichi Sankyo Inc.Estudio sin enmascaramiento en fase I para determinar el efecto de la administración de dosis repetidas de trametinib sobre la farmacocinética de un anticonceptivo oral combinado (norestisterona junto con etinilestradiol) en mujeres con tumores sólidos.
NovartisMM-121-02-02-10. Ensayo en fase II doble ciego y controlado con placebo de seribantumab más fulvestrant en mujeres posmenopáusicas con cáncer de mama metastásico positivo para receptores hormonales, positivo para herregulina (HRG+) y negativo para HER2 cuya enfermedad ha
MERRIMACK PHARMACEUTICALS INCCLEE011F2301. MONALEESA-3: Estudio aleatorizado, doble ciego, controlado con placebo de ribociclib en combinación con fulvestrant, para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2-negativo que no han recib
NOVARTIS FARMACEUTICA, S.A.CBKM120F2302. Estudio fase III aleatorizado, doble ciego, controlado con placebo de BKM120 en combinación con fulvestrant en mujeres postmenopáusicas con cáncer de mama localmente avanzado o metastásico con receptores hormonales positivos HER2 negativo que han progresa
NOVARTIS FARMACEUTICA, S.A.MO28047. Estudio multicéntrico, abierto, con un solo grupo de tratamiento, de pertuzumab en combinación con trastuzumab y un taxano como tratamiento de primera línea de pacientes con cáncer de mama avanzado (metastásico o localmente recurrente) HER2-positivo
ROCHE FARMA, S.A.20060359. Estudio multicéntrico de fase III, aleatorizado, a doble ciego y controlado con placebo de Denosumab como tratamiento adyuvante en mujeres con cáncer de mama en estado inicial con alto riesgo de recurrencia (D-CARE).
AMGEN SATTD-16-02. Estudio fase II para evaluar la eficacia de FOLFIRI + aflibercept en pacientes con cáncer colorrectal metastásico tratado previamente con oxaliplatino con o sin polimorfismos de ACE.
GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD)MO29694. Estudio de cohortes, fase II, exploratorio, multicentrico, no randomizado para determinar la mejor respuesta tumoral de trastuzumab entamsina como agente único en tumores sólidos con sobreexpresión de HER-2 (KAMALEON)
ROCHE FARMA, S.A.I3Y-MC-JPCJ. Estudio de fase 2, adaptativo, abierto, aleatorizado, en el que se compara abemaciclib en monoterapia y en combinación con otros fármacos con el estándar de tratamiento (gemcitabina o capecitabina), en pacientes con adenocarcinoma ductal de páncreas metas
LILLY, S.A.GS-US-296-1080. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de GS-5745 en combinación con mFOLFOX6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroeso
GILEAD SCIENCES, INCGEMCAD 1003. ESTUDIO FASE II ABIERTO, NO ALEATORIZADO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO NEOADYUVANTE CONCOMINANTE DE GEMCITABINA Y ERLOTINIB SEGUIDO DE GEMCITABINA, ERLOTINIB Y RADIOTERAPIA EN PACIENTES CON ADENOCARCINOMA DE PÁNCREAS
GRUPO ESPAÑOL MULTIDISCIPLINAR EN CANCER DIGESTIVOCT-4006. Ensayo en fase III adaptativo, abierto, controlado, aleatorizado para evaluar la seguridad y eficacia del EndoTAG-1 más Gemcitabina frente a Gemcitabina como monoterapia en pacientes con adenocarcinoma mensurable de páncreas metastásico y /o localmente av
SYNCORE BIOTECHNOLOGY CO., LTDCanStem111P. Estudio en fase III de la combinación de BBI-608, nab-paclitaxel y gemcitabina en pacientes adultos con adenocarcinoma pancreático metastásico
BOSTON BIOMEDICAL, INC.BA2011/03/04. Estudio abierto, controlado, aleatorizado y multicéntrico que compara la eficacia y la seguridad de infusiones intravenosas lentas repetidas de 2 dosis de doxorrubicina Transdrug™ (DT) (20 mg/m2 o 30 mg/m2) con las del mejor tratamiento de referencia (MTR
ONXEO, S.A.AM0010-301. Estudio de fase 3 aleatorizado de AM0010 combinado con FOLFOX en comparación con FOLFOX en monoterapia para el tratamiento de segunda línea en pacientes con cáncer de páncreas metastásico que ha progresado durante o después de un tratamiento de primera lí
ARMO BIOSCIENCES, INC.ABI-007-PANC-003. Estudio de fase 3, multicéntrico, abierto y aleatorizado de nab-paclitaxel más gemcitabina en comparación con gemcitabina en monoterapia como tratamiento adyuvante en sujetos con adenocarcinoma pancreático extirpado quirúrgicamente
CELGENE CORPORATIONWO29479. Estudio de fase II, multifásico, para evaluar la seguridad y la eficacia de cobimetinib en combinación con paclitaxel como tratamiento de primera línea en pacientes con cáncer de mama triple negativo metastásico
F. HOFFMANN-LA ROCHE AGGEICAM/2016-03. “ESTUDIO DE LARGO SEGUIMIENTO DE PACIENTES CON CÁNCER DE MAMA INCLUIDOS EN ESTUDIOS EN ESTADIOS PRECOCES DEL GRUPO GEICAM”.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2006-10. Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (FASLODEX) durante tres años en combinación con Anastrozol (ARIMIDEX) durante 5 años versus Anastrozol durante 5 años.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2003-10. Ensayo Clínico Multicéntrico fase III, randomizado para la comparación de la combinación de epirubicina y ciclofosmamida (EC) seguido de docetaxel (T) con Epirubicina y docetaxel (ET) seguido de capecitabina (X) en el tratamiento adyuvante de pacientes co
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2003-02. Ensayo clínico multicéntrico fase III, randomizado comparando 6 ciclos de régimen FAC (fluorouracilo, doxorubicina y ciclofosfamida) con 4 ciclos de régimen FAC seguido de 8 administraciones de Taxol semanal en régimen secuencial, como tratamiento adyuvan
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMEGF106708. Estudio fase III aleatorizado, multicéntrico, abierto de lapatinib, tratuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en pacientes on cáncer de mama HER/ErbB2 positivo
GLAXOSMITHKLINE, S.A.CLEE011E2301. Estudio fase III, aleatorizado, doble ciego, controlado con placebo de LEE011 o placebo en combinación con tamoxifeno y goserelina o de un inhibidor de la aromatasa no esteroideo (IANE) y goserelina para el tratamiento de mujeres premenopáusicas con cánc
NOVARTIS FARMACEUTICA, S.A.TTD-12-02. Ensayo clínico fase II aleatorizado para explorar la influencia del estado de BRAF y Pl3K, en la eficacia de FOLFIRI + Bevacizumab ó Cetuximab, como tratamiento de primera línea de pacientes con cáncer colorrectal metastásico con KRAS nativo y menos de tr
GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD)TTD-12-01. Ensayo clínico fase III aleatorizado, para evaluar la eficacia de FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab como tratamiento de primera línea de pacientes con cáncer colorrectal metastásico no tratado previamente con tres o más células tumorales
GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD)MK-3475-590. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de Pembrolizumab (MK-3475) en combinación con Cisplatino y 5-Fluorouracilo en comparación con Placebo en combinación con Cisplatino y 5-Fluorouracilo como tratamiento de prime
MERCK, SHARP & DOHME CORP.MedOPP107. Multicenter, open-label, phase II trial to evaluate the efficacy and safety of naI-IRI for progressing brain metastases in patients with HER2 negative breast cancer.
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR ARO)I3Y-MC-JPCF. Estudio en fase 3 aleatorizado, abierto, de abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, c
LILLY, S.A.GW572016 / EGF30008. Estudio fase III, aleatorizado, multicéntrico, doble ciego, controlado con placebo, para comparar GW572016 y letrozol frente a letrozol en pacientes con cáncer de mama avanzado o metastásico con receptores de estrógenos/progesterona positivos
GLAXOSMITHKLINE, S.A.GEICAM/2016-03. “ESTUDIO DE LARGO SEGUIMIENTO DE PACIENTES CON CÁNCER DE MAMA INCLUIDOS EN ESTUDIOS EN ESTADIOS PRECOCES DEL GRUPO GEICAM”.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2011-03_S1007. Ensayo aleatorizado, fase III, de terapia endocrina adyuvante estándar +/- quimioterapia en pacientes con cáncer de mama positivo para receptores hormonales y negativo para HER2 con afectación de 1 a 3 ganglios y con un recurrence score (RS) de 25 o infer
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2006-10. Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (FASLODEX) durante tres años en combinación con Anastrozol (ARIMIDEX) durante 5 años versus Anastrozol durante 5 años.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGEICAM/2003-08. Estudio aleatorizado fase III de tres ramas que compara Exemestano más placebo frente a Exemestano más Celecoxib y frente a placebo en mujeres postmenopaúsicas con riesgo aumentado de desarrollar cáncer de mama. V. final de 3/3/04.
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMGBG-78-BIG 1-13-NSABP-B-54-I. Estudio fase III que evalúa palbociclib (PD-0332991), un inhibidor de quinasa dependiente de las ciclinas (CDK) 4/6, en pacientes con cáncer de mama primario con receptores hormonales positivos y HER2 normal y alto riesgo de recidiva tras quimioterapia ne
GERMAN BREAST GBG FORSCHUNGSGESELLSCHAFT GMBHD3610C00002. Estudio fase I/II multicéntrico que comprende una evaluación previa de la seguridad de la combinación de AZD5363 con paclitaxel en pacientes con cáncer de mama avanzado o metastásico, seguido de una expansión aleatorizada de AZD5363 combinado con paclitax
ASTRAZENECA ABBO28407. Estudio clínico de Fase III multicéntrico, abierto, randomizado para comparar Trastuzumab en combinación con Pertuzumab más un taxano, tras quimioterapia con antriciclinas, frente a Trastuzumab Emtansina en combinación con Pertuzumab, tras quimioterapia c
ROCHE FARMA, S.A.BIG4-11/BO21126/TOC4939G. Estudio multicéntrico, doble ciego, randomizado, controlado con placebo, para comparar quimioterapia más trastuzumab y placebo con quimioterapia más trastuzumab y pertuzumab, como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positiv
F. HOFFMANN-LA ROCHE AGAPR-407. PiSARRO: Activación de la Proteína de Supresión Tumoral p53 en Carcinoma Seroso de Alto Grado recurrente en Ovario, Ensayo Clínico de Fase Ib/II de Quimioterapia Sistémica Combinada de Carboplatino/Doxorrubicina Liposomal Pegilada con o sin APR-246.
APREA ABWO29522. Estudio en Fase III, multicéntrico, aleatorizado y controlado con placebo de Atezolizumab (anticuerpo anti-PD-L1) combinado con Nab-Paclitaxel en comparación con placebo con Nab-Paclitaxel en pacientes con cáncer de mama triple negativo metastásico no tra
ROCHE FARMA, S.A.ODO-TE-B301. Estudio de fase III, aleatorizado, multicéntrico y multinacional de tesetaxel más una dosis reducida de capecitabina en comparación con capecitabina en monoterapia en pacientes con cáncer de mama metastásico o localmente avanzado, HER2 negativo y receptor
ODONATE THERAPEUTICS, INC.MEN1611-01. Estudio abierto, multicéntrico, de fase Ib, de escalado de dosis, de MEN1611, un inhibidor de PI3K combinado con trastuzumab ± fulvestrant, en sujetos con cáncer de mama irresecable y localmente recurrente (avanzado) o metastásico (a/m) HER2 positivo con
MENARINI RICERCHE S.P.A.DS8201-A-U201. Estudio abierto y multicéntrico en fase II de DS-8201a, un anti-HER2 conjugado anticuerpo-fármaco (CAF) para sujetos con cáncer de mama HER2 positivo irresecable y/o metastásico que han recibido tratamiento anteriormente con T-DM1.
DAIICHI-SANKYO, INCMedOPP100. Estudio de fase II, de dos etapas y con un diseño de Simon en pacientes con cáncer de mama metastásico (CMM), BRCA negativo, con deficiencia en la recombinación homóloga tratada con olaparib en monoterapia (estudio NOBROLA)
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR ARO)M12-914. Ensayo fase III aleatorizado y controlado con placebo, de carboplatino y paclitaxel con o sin el inhibidor de PARP veliparib (ABT-888) en cáncer de mama asociado a BRCA, HER2 negativo, no resecable, metastásico o localmente avanzado
ABBVIE DEUTCHSLAND GMBH & CON K. GCD-ON-MEDI-573-1030. Estudio de fase 1b/2 aleatorizado de MEDI-573 en combinación con un inhibidor de la aromatasa (IA) frente a un IA en monoterapia en mujeres con cáncer de mama metastásico (CMM).
MEDIMMUNE LLCONT-380-206. Estudio de fase 2, doble ciego, aleatorizado y controlado, de tucatinib frente a placebo en combinación con capecitabina y trastuzumab en pacientes con carcinoma de mama HER2+ inextirpable localmente avanzado o metastásico con tratamiento previo (HER2CLIM
CASCADIAN THERAPEUTICS INC.MO28231. Estudio multicéntrico, con un solo grupo de tratamiento, de trastuzumab emtansina (TDM1) en pacientes con cáncer de mama localmente avanzado o metastásico, HER2 positivo, que han recibido previamente tratamiento basado en un agente anti-HER2 y quimioterap
F. HOFFMANN-LA ROCHE AGGEICAM/2014-12. Estudio fase II, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, para comparar la eficacia y tolerabilidad de Fulvestrant (FaslodexTM) 500mg con placebo y Fulvestrant (FaslodexTM) 500mg en combinación con el PD-0332991 (Palbociclib) como pr
FUNDACION GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER MAMACTMT212X2102. Estudio sin enmascaramiento en fase I para determinar el efecto de la administración de dosis repetidas de trametinib sobre la farmacocinética de un anticonceptivo oral combinado (noretindrona junto con etinilestradiol) en pacientes mujeres con tumores s
NOVARTIS FARMACEUTICA, S.A.1280-0022. XENERA-1: Ensayo de Fase II multicéntrico, doble-ciego, controlado con placebo y aleatorizado para comparar la eficacia de xentuzumab en combinación con everolimus y exemestano frente a everolimus y exemestano en mujeres posmenopáusicas con cáncer de mam
BOEHRINGER INGELHEIM ESPAÑA, S.A.BAY 88-8223/17096. Estudio de fase II aleatorizado, doble ciego, controlado con placebo, de dicloruro de radio-223 combinado con exemestano y everolimús, en comparación con un placebo combinado con exemestano y everolimús cuando se administra a sujetos con cáncer de mama me
BAYER HEALTHCARE AGMedOPP096-MO39229. Trastuzumab y pertuzumab sin quimioterapia en cáncer de mama HER2 positivo: estrategia adaptada en función de la respuesta evaluada por FDG-PET. Estudio PHERGain
MEDICA SCIENTIA INNOVATION RESEARCH, S.L. (MEDSIR ARO)TTD-18-01. Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de FOLFOX + panitumumab seguido por FOLFIRI + bevacizumab (Secuencia 1) frente a FOLFOX + bevacizumab seguido por FOLFIRI + panitumumab (Secuencia 2) en pacientes con cáncer
GRUPO DE TRATAMIENTO DE TUMORES DIGESTIVOS (TTD)BO27938. Estudio de Fase III, abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de trastuzumab emtansine versus trastuzumab como tratamiento adyuvante en pacientes con cáncer de mama primario HER2-positivo con presencia patológica de tumor
ROCHE FARMA, S.A.GEICAM/2013-02. Estudio fase III de Palbociclib (PD-0332991) en combinación con Exemestano frente a quimioterapia (capecitabina) en pacientes con Cáncer de Mama Avanzado (CMA) con Receptores Hormonales (RH) positivos y HER2 negativo con Resistencia a inhibidores de Aroma
GRUPO ESPAÑOL DE INVESTIGACION EN EL CANCER DE MAMA GEICAMCLEE011A2404. COMPLEEMENT-1: Estudio de fase IIIb, abierto, multicéntrico, para evaluar la seguridad y la eficacia de ribociclib (LEE011) en combinación con letrozol en el tratamiento de hombres y mujeres pre/postmenopáusicas con cáncer de mama avanzado (CMA) con recep
NOVARTIS FARMACEUTICA, S.A.CLEE011A2301. Estudio aleatorizado, doble ciego, controlado con placebo, de LEE011 en combinación con letrozol para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2-negativo que no han recibido terapia previa p
NOVARTIS FARMACEUTICA, S.A.BO28408. Estudio Fase III multicéntrico, aleatorizado, abierto, con dos brazos de tratamiento neoadyuvante, para evaluar trastuzumab emtansina más pertuzumab comparado con quimioterapia más trastuzumab y pertuzumab en pacientes con cáncer de mama HER2 positivo. Es
F. HOFFMANN LA ROCHE LTDAFT-05/ABCSG-42/BIG_14-03. PALLAS (PALbociclib CoLlaborative Adjuvant Study):Ensayo de fase III aleatorizado de palbociclib con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar en cáncer de mama precoz con receptores hormon
AUSTRIAN BREAST & COLORECTAL CANCER GROUP (ABCSG)3475-119. Ensayo aleatorizado, abierto, de fase III con pembrolizumab en monoterapia frente a quimioterapia con agente único a elección del médico para cáncer de mama triplemente negativo metastásico (CMTNm) (KEYNOTE-119)
MERCK SHARP & DOHME DE ESPAÑA SASRA737-02. Ensayo en fase I/II de SRA737 (un inhibidor de Chk1) administrado por vía oral en combinación con gemcitabina más cisplatino o gemcitabina únicamente en pacientes con cáncer avanzado.
Sierra Oncology, Inc.D081CC00006. “Ensayo fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de olaparib frente a placebo como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto
ASTRAZENECA ABD0816C00014. Estudio de Fase IIIb, aleatorizado, en doble ciego, controlado con placebo y multicéntrico, del retratamiento con olaparib en pacientes con cáncer epitelial de ovario tratado previamente con un PARPi y con respuesta a la repetición de la quimioterapia con
ASTRAZENECA ABCO-338-014. Ensayo multicéntrico de Fase III, aleatorizado, doble ciego y controlado con placebo del Rucaparib como tratamiento de mantenimiento después de la quimioterapia de platino en pacientes con carcinoma de Trompa de Falopio, cardinoma primario de peritoneo o
CLOVIS ONCOLOGY INCIMGN-0403. FORWARD1: Estudio abierto de fase III aleatorizado para evaluar la seguridad y la eficacia de mirvetuximab soravtansina (IMGN853) frente a la elección del investigador de quimioterapia en mujeres con cáncer de las trompas de Falopio, cáncer peritoneal pri
IMMUNOGEN INCENGOT-EN2-DGCG. Ensayo de fase III de quimioterapia postoperatoria frente a ningún tratamiento posterior en pacientes con cáncer de endometrio de riesgo intermedio o alto, en estadios I o II, con ganglios negativos
DANISH GYNAECOLOGICAL CANCER GROUP DANISH GYNAECOLOGICAL CANCER GROUPAFT-38. Ensayo de fase III, aleatorizado y abierto para evaluar la eficacia y la seguridad de palbociclib + tratamiento anti-HER2 + tratamiento endocrino frente a tratamiento anti-HER2 + tratamiento endocrino tras el tratamiento de inducción para el cáncer de mam
Alliance Foundation Trials, LLC3144A2-3004-WW. Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobrexpresión/amplificación de HER-2/neu.
PFIZER, S.A PUMA BIOTECNOLOGY INCPatentes y Tecnologías
Queipo Ortuño, María Isabel
Emilio Alba Conejo
Plaza Andrade, Isaac
Sanchez Alcoholado, Lidia
Laborda Illanes, Aurora
Castellano Castillo, Daniel
Emilio Alba Conejo
Plaza Andrade, Isaac
Sanchez Alcoholado, Lidia
Laborda Illanes, Aurora
Castellano Castillo, Daniel
Sanchez Alcoholado, Lidia
Laborda Illanes, Aurora
Castellano Castillo, Daniel
Castellano Castillo, Daniel
Panel de secuenciación para biopsia líquida de pacientes con cáncer de mama
Comino Méndez, Iñaki
Emilio Alba Conejo
Alba Bernal, Alfonso
Jimenez Rodríguez, Begoña
Quirós Ortega, María Elena
Emilio Alba Conejo
Alba Bernal, Alfonso
Jimenez Rodríguez, Begoña
Quirós Ortega, María Elena
Jimenez Rodríguez, Begoña
Quirós Ortega, María Elena
Método para predecir la respuesta a inmunoterapia en pacientes con melanoma cutáneo
Barragán Mallofret, María Isabel
Emilio Alba Conejo
Berciano Guerrero, Miguel angel
Pérez Ruiz, Elisabeth
Rueda Domínguez, Antonio
Onieva Zafra, Juan Luis
Oliver Martos, Francisco Javier
Emilio Alba Conejo
Berciano Guerrero, Miguel angel
Pérez Ruiz, Elisabeth
Rueda Domínguez, Antonio
Onieva Zafra, Juan Luis
Oliver Martos, Francisco Javier
Pérez Ruiz, Elisabeth
Rueda Domínguez, Antonio
Onieva Zafra, Juan Luis
Oliver Martos, Francisco Javier
Onieva Zafra, Juan Luis
Oliver Martos, Francisco Javier
Biomarcadores para predecir la respuesta al tratamiento de pacientes con melanoma metastásico
Berciano Guerrero, Miguel angel
Lavado Valenzuela, Maria del Rocio
Moya García, Aurelio Ángel
Emilio Alba Conejo
Rueda Domínguez, Antonio
Montesa Pino, Alvaro
Navas Delgado, Ismael
Lavado Valenzuela, Maria del Rocio
Moya García, Aurelio Ángel
Emilio Alba Conejo
Rueda Domínguez, Antonio
Montesa Pino, Alvaro
Navas Delgado, Ismael
Emilio Alba Conejo
Rueda Domínguez, Antonio
Montesa Pino, Alvaro
Navas Delgado, Ismael
Montesa Pino, Alvaro
Navas Delgado, Ismael
Método para predecir la respuesta del cáncer al tratamiento con inmunoterapia con anti-PD1.
Barragán Mallofret, María Isabel
Emilio Alba Conejo
Berciano Guerrero, Miguel angel
Cobo Dols, Manuel
Álvarez Pérez, Martina
Garrido Aranda, Alicia
Sánchez Muñoz, Alfonso
Oliver Martos, Francisco Javier
Emilio Alba Conejo
Berciano Guerrero, Miguel angel
Cobo Dols, Manuel
Álvarez Pérez, Martina
Garrido Aranda, Alicia
Sánchez Muñoz, Alfonso
Oliver Martos, Francisco Javier
Cobo Dols, Manuel
Álvarez Pérez, Martina
Garrido Aranda, Alicia
Sánchez Muñoz, Alfonso
Oliver Martos, Francisco Javier
Garrido Aranda, Alicia
Sánchez Muñoz, Alfonso
Oliver Martos, Francisco Javier
Oliver Martos, Francisco Javier
Kit para pronosticar el riesgo de recidiva en cáncer de mama
Emilio Alba Conejo
Lozano Castro, José
Jerez Aragones, Jose Manuel
Ribelles Entrena, Nuria
Lozano Castro, José
Jerez Aragones, Jose Manuel
Ribelles Entrena, Nuria
Ribelles Entrena, Nuria
Publicaciones científicas
- Todo
- D1
- Q1
- Q2
- Otro
14-3-3 zeta is crucial for the conversion of labile short-term object recognition memory into stable long-term memory
Navarro-Lobato I, Masmudi-Martín M, Quiros-Ortega ME, Gaona-Romero C, Carretero-Rey M, et al. Journal of neuroscience research 2021 Sep;99(9):2305-2317
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, et al. The New England journal of medicine 2021 Dec 16;385(25):2336-2347
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, et al. Cancers 2021 Feb 14;13(4):
A New Paradigm in the Relationship between Melatonin and Breast Cancer: Gut Microbiota Identified as a Potential Regulatory Agent
Laborda-Illanes A, Sánchez-Alcoholado L, Boutriq S, Plaza-Andrades I, Peralta-Linero J, et al. Cancers 2021 Jun 23;13(13):
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe
Vrdoljak E, Gligorov J, Wierinck L, Conte P, De Grève J, et al. Breast (Edinburgh, Scotland) 2021 Feb;55():79-90
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Oct 20;39(30):3391-3402
An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: a pilot study
Mateo-Gallego R, Moreno-Indias I, Bea AM, Sánchez-Alcoholado L, Fumanal AJ, et al. Food & function 2021 Apr 21;12(8):3635-3646
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study
Ruano-Ravina A, Provencio M, Calvo de Juan V, Carcereny E, Estival A, et al. Translational lung cancer research 2021 Oct;10(10):3902-3911
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Hawkes EA, Phillips T, Budde LE, Santoro A, Saba NS, et al. Targeted oncology 2021 Nov;16(6):761-771
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Harding JJ, Moreno V, Bang YJ, Hong MH, Patnaik A, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Apr 15;27(8):2168-2178
Chemotherapy de-escalation using an F-18-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, et al. The Lancet. Oncology 2021 Jun;22(6):858-871
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
Bazhenova L, Minchom A, Viteri S, Bauml JM, Ou SI, et al. Lung cancer (Amsterdam, Netherlands) 2021 Dec;162():154-161
CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients
Sánchez-Torralvo FJ, Ruiz-García I, Contreras-Bolívar V, González-Almendros I, Ruiz-Vico M, et al. Nutrients 2021 Jul 30;13(8):
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis
Fudio S, Tabernero J, Subbiah V, Chawla SP, Moreno V, et al. Cancer chemotherapy and pharmacology 2021 Jan;87(1):113-124
Electronic health records and patient registries in medical oncology departments in Spain
Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 Oct;23(10):2099-2108
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, et al. PloS one 2021;16(6):e0251761
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, et al. Drugs & aging 2021 Mar;38(3):219-231
Genome Profiling of H3k4me3 Histone Modification in Human Adipose Tissue during Obesity and Insulin Resistance
Castellano-Castillo D, Ramos-Molina B, Oliva-Olivera W, Ocaña-Wilhelmi L, Queipo-Ortuño MI, et al. Biomedicines 2021 Sep 30;9(10):
Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer
Boutriq S, González-González A, Plaza-Andrades I, Laborda-Illanes A, Sánchez-Alcoholado L, et al. Journal of personalized medicine 2021 Jul 14;11(7):
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, et al. The Lancet. Oncology 2021 May;22(5):665-677
Histamine, Metabolic Remodelling and Angiogenesis: A Systems Level Approach
Moya-García AA, Pino-Ángeles A, Sánchez-Jiménez F, Urdiales JL, Medina MÁ Biomolecules 2021 Mar 11;11(3):
Impact of weight loss on cancer patients’ quality of life at the beginning of the chemotherapy
Álvaro Sanz E, Abilés J, Garrido Siles M, Pérez Ruíz E, Alcaide García J, et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021 Feb;29(2):627-634
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study
Martín-Bravo C, Quirós R, Blancas I, Villatoro-Roldán R, Robles M, et al. Seminars in oncology 2021 Apr;48(2):145-151
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Jul 10;39(20):2304-2312
Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, et al. Hematological oncology 2021 Oct;39(4):506-512
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, et al. Cancer medicine 2021 Sep;10(17):5878-5888
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients
Ribelles N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, Diaz-Redondo T, et al. European journal of cancer (Oxford, England : 1990) 2021 Feb;144():224-231
Ocular side effects of checkpoint inhibitors
Alba-Linero C, Alba E Survey of ophthalmology 2021 Nov-Dec;66(6):951-959
Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, et al. European journal of cancer (Oxford, England : 1990) 2021 Oct;156():70-82
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Jan 15;27(2):460-472
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2021 Apr;32(4):488-499
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)
Benavent M, Sastre J, Escobar IG, Segura A, Capdevila J, et al. Health and quality of life outcomes 2021 Jan 30;19(1):38
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma
Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, et al. Scientific reports 2021 Jan 21;11(1):1886
Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
Blancas I, Olier C, Conde V, Bayo JL, Herrero C, et al. Scientific reports 2021 Feb 19;11(1):4274
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome
Ruiz-Pinto S, Pita G, Martín M, Nuñez-Torres R, Cuadrado A, et al. Clinical pharmacology and therapeutics 2021 Feb;109(2):462-470
Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients
Sánchez-Alcoholado L, Laborda-Illanes A, Otero A, Ordóñez R, González-González A, et al. International journal of molecular sciences 2021 Sep 2;22(17):
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients
Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, et al. European urology oncology 2021 Apr;4(2):315-318
SEOM clinical guidelines for the treatment of head and neck cancer (2020)
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 May;23(5):913-921
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study
Ruiz-Medina S, Gil S, Jimenez B, Rodriguez-Brazzarola P, Diaz-Redondo T, et al. Cancers 2021 Jun 28;13(13):
Structural validity and reliability of the Spanish Central Sensitization Inventory in breast cancer survivors
Roldán-Jiménez C, Pajares B, Iglesias Campos M, Trinidad-Fernández M, Gutiérrez-Sánchez D, et al. Pain practice : the official journal of World Institute of Pain 2021 Sep;21(7):740-746
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naive Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial
Grande E, Rodriguez-Antona C, López C, Alonso-Gordoa T, Benavent M, et al. The oncologist 2021 Nov;26(11):941-949
The role of CDK4/6 inhibitors in early breast cancer
Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, et al. Breast (Edinburgh, Scotland) 2021 Aug;58():160-169
Transformers for Clinical Coding in Spanish
Lopez-Garcia, G; Jerez, JM; Ribelles, N; Alba, E; Veredas, FJ IEEE ACCESS 2021
Ultrasound use in metastatic breast cancer to measure body composition changes following an exercise intervention
Escriche-Escuder A, Trinidad-Fernández M, Pajares B, Iglesias-Campos M, Alba E, et al. Scientific reports 2021 Apr 23;11(1):8858
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, et al. Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.] 2021 Jan;21(1):215-223
Validity and reliability of the Spanish fear-avoidance components scale in breast cancer survivors
Gutiérrez-Sánchez D, Roldán-Jiménez C, Pajares B, Alba E, Cuesta-Vargas AI European journal of cancer care 2021 Nov;30(6):e13506
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, et al. Investigational new drugs 2020 Apr;38(2):457-467
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Oct;15(10):1647-1656
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, et al. Frontiers in oncology 2020;10():578756
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, et al. Lung cancer (Amsterdam, Netherlands) 2020 Dec;150():90-96
AR-V7as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A HypotheticalCost-SavingAnalysis
Pacheco-Orozco RA, Montealegre-Páez L, Cayol F, Martínez-Gregorio H, Oliver J, et al. The oncologist 2020 Dec;25(12):e1990-e1995
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment
Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, Jimenez-Rodriguez B, Lavado R, et al. Cancers 2020 Aug 31;12(9):
Challenges and achievements of liquid biopsy technologies employed in early breast cancer
Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, Jiménez-Rodriguez B, Queipo-Ortuño MI, et al. EBioMedicine 2020 Dec;62():103100
Characterization of the Human Exposome by a Comprehensive and Quantitative Large-Scale Multianalyte Metabolomics Platform
González-Domínguez R, Jáuregui O, Queipo-Ortuño MI, Andrés-Lacueva C Analytical chemistry 2020 Oct 20;92(20):13767-13775
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, et al. European journal of cancer (Oxford, England : 1990) 2020 Mar;127():160-172
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, et al. British journal of cancer 2020 May;122(10):1461-1466
Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic
Rojas-Jiménez E, Mejía-Gómez JC, Díaz-Velásquez C, Quezada-Urban R, Martínez Gregorio H, et al. Genes 2020 Nov 19;11(11):
Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjogren’s Syndrome
Cano-Ortiz A, Laborda-Illanes A, Plaza-Andrades I, Membrillo Del Pozo A, Villarrubia Cuadrado A, et al. International journal of molecular sciences 2020 Nov 19;21(22):
Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion
Fernández-Montes A, Grávalos C, Pericay C, Safont MJ, Benavides M, et al. Clinical colorectal cancer 2020 Sep;19(3):165-177
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, et al. JAMA oncology 2020 May 1;6(5):661-674
EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin alpha(V)beta(3)in cancer cells
Gasca J, Flores ML, Jiménez-Guerrero R, Sáez ME, Barragán I, et al. Cell death discovery 2020;6():86
Energy System Assessment in Survivors of Breast Cancer
Cuesta-Vargas AI, Buchan J, Pajares B, Alba E, Trinidad-Fernández M, et al. Physical therapy 2020 Mar 10;100(3):438-446
Epigenetic regulation of white adipose tissue in the onset of obesity and metabolic diseases
Castellano-Castillo D, Ramos-Molina B, Cardona F, Queipo-Ortuño MI Obesity reviews : an official journal of the International Association for the Study of Obesity 2020 Nov;21(11):e13054
Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade
Barragan I, Barragan I EBioMedicine 2020 Oct;60():103005
Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancer
Arroyo M, Larrosa R, Gómez-Maldonado J, Cobo MÁ, Claros MG, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Oct;22(10):1867-1874
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Nishio M, Felip E, Orlov S, Park K, Yu CJ, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Apr;15(4):609-617
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao Q, Nobre A, Piñeiro P, Berciano-Guerrero MÁ, Alba E, et al. Journal of clinical medicine 2020 Jan 20;9(1):
Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer
Sánchez-Alcoholado L, Ordóñez R, Otero A, Plaza-Andrade I, Laborda-Illanes A, et al. International journal of molecular sciences 2020 Sep 16;21(18):
Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
Pérez-Ruiz E, Jiménez-Castro J, Berciano-Guerrero MA, Valdivia J, Estalella-Mendoza S, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Oct;22(10):1778-1785
Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival
Boughanem H, Martin-Nuñez GM, Torres E, Arranz-Salas I, Alcaide J, et al. Journal of personalized medicine 2020 Nov 11;10(4):
Inertial Sensors Embedded in Smartphones as a Tool for Fatigue Assessment Based on Acceleration in Survivors of Breast Cancer
Cuesta-Vargas AI, Pajares B, Trinidad-Fernandez M, Alba E, Roldan-Jiménez C Physical therapy 2020 Mar 10;100(3):447-456
Lung cancer symptoms at diagnosis: results of a nationwide registry study
Ruano-Raviña A, Provencio M, Calvo de Juan V, Carcereny E, Moran T, et al. ESMO open 2020 Nov;5(6):e001021
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Trigo J, Subbiah V, Besse B, Moreno V, López R, et al. The Lancet. Oncology 2020 May;21(5):645-654
Measurement of Serum Testosterone in Nondiabetic Young Obese Men: Comparison of Direct Immunoassay to Liquid Chromatography-Tandem Mass Spectrometry
Martínez-Escribano A, Maroto-García J, Ruiz-Galdón M, Barrios-Rodríguez R, Álvarez-Millán JJ, et al. Biomolecules 2020 Dec 19;10(12):
Microbial Signature in Adipose Tissue of Crohn’s Disease Patients
Serena C, Queipo-Ortuño M, Millan M, Sanchez-Alcoholado L, Caro A, et al. Journal of clinical medicine 2020 Jul 31;9(8):
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, et al. The Lancet. Oncology 2020 Nov;21(11):1413-1422
Ocular surface characterization after allogeneic stem cell transplantation: A prospective study in a referral center
Alba-Linero C, Rodriguez Calvo de Mora M, Lavado Valenzuela R, Pascual Cascón MJ, Martín Cerezo AR, et al. Indian journal of ophthalmology 2020 Aug;68(8):1556-1562
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, et al. The New England journal of medicine 2020 Jan 2;382(1):41-50
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, et al. The New England journal of medicine 2020 Dec 3;383(23):2207-2218
Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results
Carrato A, Vieitez JM, Benavides M, Rodriguez-Garrote M, Castillo A, et al. European journal of cancer (Oxford, England : 1990) 2020 Nov;139():51-58
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
Sepúlveda-Sánchez JM, Gil-Gil M, Alonso-García M, Vaz Salgado MÁ, Vicente E, et al. Targeted oncology 2020 Oct;15(5):613-622
Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
Campos-Balea B, de Castro Carpeño J, Massutí B, Vicente-Baz D, Pérez Parente D, et al. Thoracic cancer 2020 Nov;11(11):3357-3364
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA
Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Jan;15(1):138-143
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, et al. Cancers 2020 Jul 22;12(8):
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
Alvarez-Lopez I, Bezares S, Dalmau Portulas E, García-Martínez E, García-Sáenz JÁ, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Aug;22(8):1364-1377
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
García-Muñoz R, Quero C, Pérez-Persona E, Domingo-García A, Pérez-López C, et al. British journal of haematology 2020 Mar;188(5):661-673
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
Dómine M, Moran T, Isla D, Martí JL, Sullivan I, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Feb;22(2):245-255
Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain
Segui MA, Cruz JJ, Alba E, Feliu J, Jara C, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Jul;22(7):1049-1058
Subclinical Arteriosclerosis is Associated with Common Vascular Risk Factors in Long-Term Survivors of Testicular Cancer
Espíldora-Hernández J, Díaz-Antonio T, Baena-Espinar J, Alonso-Calderón I, Rioja J, et al. Journal of clinical medicine 2020 Mar 31;9(4):
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response
Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, et al. Cancers 2020 May 29;12(6):
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 May;22(5):759-771
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Feliu J, Garcia-Carbonero R, Capdevila J, Guasch I, Alonso-Orduna V, et al. Cancer medicine 2020 Feb;9(3):1008-1016
18FDG PET/CT & arterial inflammation: predicting cardiovascular events in lung cancer
Villena García AC, Cardo AG, Hidalgo CM, Palomo L, Lillo E, et al. QJM : monthly journal of the Association of Physicians 2019 Jun 1;112(6):401-407
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, et al. Frontiers in oncology 2019;9():303
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
Villaruz LC, Cobo M, Syrigos K, Mavroudis D, Zhang W, et al. Lung cancer (Amsterdam, Netherlands) 2019 Oct;136():52-56
Altered Adipose Tissue DNA Methylation Status in Metabolic Syndrome: Relationships Between Global DNA Methylation and Specific Methylation at Adipogenic, Lipid Metabolism and Inflammatory Candidate Genes and Metabolic Variables
Castellano-Castillo D, Moreno-Indias I, Sanchez-Alcoholado L, Ramos-Molina B, Alcaide-Torres J, et al. Journal of clinical medicine 2019 Jan 13;8(1):
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer
Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Feb;14(2):304-310
Biomarker potential of repetitive-element transcriptome in lung cancer
Arroyo M, Bautista R, Larrosa R, Cobo MÁ, Claros MG PeerJ 2019;7():e8277
Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index
Cuesta-Vargas A, Buchan J, Pajares B, Alba E, Roldan-Jiménez C PloS one 2019;14(4):e0215662
Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy
Zapata I, Alvarez M, Hidalgo R, Pajares B, Garcia-Anaya MJ, et al. BMC cancer 2019 Dec 21;19(1):1241
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 Feb 1;30(2):290-296
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, et al. Scientific reports 2019 Jun 20;9(1):8976
Cross-sectional, Primary Care-Based Study of the Prevalence of Hypoandrogenemia in Nondiabetic Young Men with Obesity
Molina-Vega M, Asenjo-Plaza M, García-Ruiz MC, Varea-Marineto E, Casal-Nievas N, et al. Obesity (Silver Spring, Md.) 2019 Oct;27(10):1584-1590
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma
Lauschke VM, Nordling Å, Zhou Y, Fontalva S, Barragan I, et al. Pharmacogenomics 2019 Oct;20(15):1085-1092
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Godoy-Ortiz A, Sanchez-Muñoz A, Chica Parrado MR, Álvarez M, Ribelles N, et al. Frontiers in oncology 2019;9():1124
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Rodriguez BJ, Córdoba GD, Aranda AG, Álvarez M, Vicioso L, et al. Journal of clinical medicine 2019 Aug 7;8(8):
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, et al. Frontiers in oncology 2019;9():1178
Effects of SHBG rs1799941 Polymorphism on Free Testosterone Levels and Hypogonadism Risk in Young Non-Diabetic Obese Males
Castellano-Castillo D, Royo JL, Martínez-Escribano A, Sánchez-Alcoholado L, Molina-Vega M, et al. Journal of clinical medicine 2019 Jul 31;8(8):
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, et al. Breast cancer research and treatment 2019 Apr;174(3):693-701
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, et al. BMC cancer 2019 Jun 3;19(1):533
Gender-Related Differences on Polyamine Metabolome in Liquid Biopsies by a Simple and Sensitive Two-Step Liquid-Liquid Extraction and LC-MS/MS.
Samarra I, Ramos-Molina B, Queipo-Ortuño MI, Tinahones FJ, Arola L, et al. Biomolecules 2019 Nov 26;9(12):
GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients
Contreras-Bolívar V, Sánchez-Torralvo FJ, Ruiz-Vico M, González-Almendros I, Barrios M, et al. Nutrients 2019 Sep 1;11(9):
Human adipose tissue H3K4me3 histone mark in adipogenic, lipid metabolism and inflammatory genes is positively associated with BMI and HOMA-IR
Castellano-Castillo D, Denechaud PD, Fajas L, Moreno-Indias I, Oliva-Olivera W, et al. PloS one 2019;14(4):e0215083
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, et al. Cancer immunology, immunotherapy : CII 2019 Mar;68(3):341-352
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, et al. Breast cancer research and treatment 2019 Sep;177(2):383-393
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, et al. European journal of cancer (Oxford, England : 1990) 2019 Jan;107():124-132
Morphological MRI-based features provide pretreatment survival prediction in glioblastoma
Pérez-Beteta J, Molina-García D, Martínez-González A, Henares-Molina A, Amo-Salas M, et al. European radiology 2019 Apr;29(4):1968-1977
Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)
Santaballa A, De Castro J, Maurel J, Lázaro M, Vera R, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Apr;21(4):534-538
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Oct;14(10):1828-1838
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Jan 20;37(3):230-238
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, et al. Breast cancer research and treatment 2019 Aug;177(1):115-125
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, et al. Nature 2019 May;569(7756):428-432
PSEUDOVITELLIFORM MACULOPATHY SECONDARY TO BRAF AND MEK INHIBITORS IN A PATIENT WITH METASTASIC MELANOMA
Alba-Linero C, Rocha De Lossada C, Delgado-Fernández AS, Jódar-Márquez M, Rodríguez Calvo De Mora M, et al. Journal of biological regulators and homeostatic agents 2019 September-October,;33(5):1497-1500
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, et al. The oncologist 2019 Aug;24(8):1095-1102
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Jan;21(1):46-54
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)
González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Jan;21(1):55-63
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem M, Juan O, Insa A, Reguart N, Trigo JM, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Jan;21(1):3-17
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).
Lopez-Tarruella S, Escudero MJ, Pollan M, Martín M, Jara C, et al. Scientific reports 2019 Dec 27;9(1):20081
Targeted treatment approaches in refractory germ cell tumors
Galvez-Carvajal L, Sanchez-Muñoz A, Ribelles N, Saez M, Baena J, et al. Critical reviews in oncology/hematology 2019 Nov;143():130-138
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Nov 15;25(22):6644-6652
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, et al. Hematological oncology 2019 Apr;37(2):143-150
Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group
Aparicio J, Sánchez-Muñoz A, Ochenduszko S, Gumà J, Fernández-Aramburo A, et al. The Journal of urology 2019 Oct;202(4):742-747
Type 2 Diabetes Is Associated with a Different Pattern of Serum Polyamines: A Case-Control Study from the PREDIMED-Plus Trial
Fernandez-Garcia JC, Delpino-Rius A, Samarra I, Castellano-Castillo D, Muñoz-Garach A, et al. Journal of clinical medicine 2019 Jan 10;8(1):
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
González-Rincón J, Méndez M, Gómez S, García JF, Martín P, et al. PloS one 2019;14(2):e0212813
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Dec 1;25(23):7035-7045
VIGLA-M: visual gene expression data analytics
Navas-Delgado, I; Garcia-Nieto, J; Lopez-Camacho, E; Rybinski, M; Lavado, R; Guerrero, MAB; Aldana-Montes, JF BMC BIOINFORMATICS 2019
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, et al. Lung cancer (Amsterdam, Netherlands) 2018 Jun;120():27-33
A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study
Aparicio J, Sánchez-Muñoz A, Gumà J, Domenech M, Meana JA, et al. Oncology 2018;95(1):8-12
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)
Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, et al. Cancer 2018 Dec 15;124(24):4667-4675
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Goss GD, Felip E, Cobo M, Lu S, Syrigos K, et al. JAMA oncology 2018 Sep 1;4(9):1189-1197
Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
Godoy-Ortiz A, Plata Y, Alcaide J, Galeote A, Pajares B, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jul;20(7):922-927
Central sensitization in breast cancer survivors
Cuesta-Vargas, AI; Roldan-Jimenez, C; Pajares, B; Alba, E JOURNAL OF APPLIED BIOBEHAVIORAL RESEARCH 2018
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aug 28;():JCO2018783118
Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial
Conejo I, Pajares B, Alba E, Cuesta-Vargas AI BMC complementary and alternative medicine 2018 Jun 11;18(1):180
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jul;20(7):862-869
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, et al. The Lancet. Respiratory medicine 2018 Oct;6(10):771-781
Experience with eribulin in triple-negative metastatic breast cancer: case studies
Gallegos Sancho MI, Márquez-Vázquez R, Sánchez-Muñoz A Future oncology (London, England) 2018 Mar;14(7s):13-20
Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer
Pérez-Ruiz E, Rueda A, Pérez L, Rivas-Ruiz F, Torres E, et al. Pathology oncology research : POR 2018 Oct;24(4):871-879
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Aranda E, García-Alfonso P, Benavides M, Sánchez Ruiz A, Guillén-Ponce C, et al. European journal of cancer (Oxford, England : 1990) 2018 Sep;101():263-272
First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, et al. Breast cancer research and treatment 2018 Jun;169(3):469-479
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial
Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2018 Feb 1;29(2):439-444
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, et al. Breast cancer research and treatment 2018 Aug;170(3):535-545
Hereditary breast and ovarian cancer in Andalusian families: a genetic population study
Pajares B, Porta J, Porta JM, Sousa CF, Moreno I, et al. BMC cancer 2018 Jun 8;18(1):647
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2018 Oct 1;29(10):2076-2084
Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers
Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, et al. PloS one 2018;13(4):e0194844
Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer
Manso L, Sanchez-Muñoz A, Calvo I, Izarzugaza Y, Plata J, et al. Breast care (Basel, Switzerland) 2018 Aug;13(4):277-283
Long non-coding RNA p10247, high expressed in breast cancer (lncRNA-BCHE), is correlated with metastasis
Yang YX, Wei L, Zhang YJ, Hayano T, Piñeiro Pereda MDP, et al. Clinical & experimental metastasis 2018 Mar;35(3):109-121
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Feb;31(2):299-306
Management of hyperbilirubinaemia in pancreatic cancer patients
Álvarez R, Carrato A, Adeva J, Alés I, Prados S, et al. European journal of cancer (Oxford, England : 1990) 2018 May;94():26-36
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study
Ethier JL, Ocaña A, Rodríguez Lescure A, Ruíz A, Alba E, et al. European journal of cancer (Oxford, England : 1990) 2018 May;94():199-205
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Lauschke VM, Barragan I, Ingelman-Sundberg M Annual review of pharmacology and toxicology 2018 Jan 6;58():161-185
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study
Fernández A, Salgado M, García A, Buxò E, Vera R, et al. BMC cancer 2018 Nov 29;18(1):1185
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Dec;20(12):1548-1556
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, et al. British journal of cancer 2018 Dec;119(12):1464-1470
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
Esteban I, Vilaró M, Adrover E, Angulo A, Carrasco E, et al. Psycho-oncology 2018 Jun;27(6):1530-1537
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, et al. Breast cancer research and treatment 2018 Feb;167(3):659-669
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Ciruelos E, Vidal M, Martínez de Dueñas E, Martínez-Jáñez N, Fernández Y, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jun;20(6):753-760
SEOM clinical guidelines for anaplastic gliomas (2017)
Balañá C, Alonso M, Hernandez-Lain A, Hernandez A, Perez-Segura P, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018 Jan;20(1):16-21
Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers
Chin SF, Santonja A, Grzelak M, Ahn S, Sammut SJ, et al. Experimental and molecular pathology 2018 Jun;104(3):161-169
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
García-Alfonso P, Benavides M, Falcó E, Muñoz A, Gómez A, et al. The oncologist 2018 Nov;23(11):1271-e128
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, et al. Clinical lung cancer 2018 Jan;19(1):74-83.e11
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, et al. Nature communications 2018 Jul 24;9(1):2897
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, et al. European journal of cancer (Oxford, England : 1990) 2018 Feb;90():63-72
Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma
Pérez-Beteta J, Molina-García D, Ortiz-Alhambra JA, Fernández-Romero A, Luque B, et al. Radiology 2018 Jul;288(1):218-225
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice
Molina-Vega M, García-Alemán J, Sebastián-Ochoa A, Mancha-Doblas I, Trigo-Pérez JM, et al. Endocrine 2018 Feb;59(2):395-401
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Aug;13(8):1156-1170
A consensus statement on the gender perspective in lung cancer
Isla D, Majem M, Viñolas N, Artal A, Blasco A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 May;19(5):527-535
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
González A, Lluch A, Aba E, Albanell J, Antón A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 May;19(5):616-624
A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients
García JL, Lozano R, Misiewicz-Krzeminska I, Fernández-Mateos J, Krzeminski P, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Nov;19(11):1350-1357
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 15;23(12):3035-3044
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Ocana A, Gil-Martin M, Martín M, Rojo F, Antolín S, et al. Oncotarget 2017 Sep 22;8(42):73144-73153
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, et al. Investigational new drugs 2017 Oct;35(5):634-641
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Glisson B, Besse B, Dols MC, Dubey S, Schupp M, et al. Clinical lung cancer 2017 Nov;18(6):615-625.e8
An immunohistochemical study of cytokeratins distribution of the human adult male and female urethra
Herrera-Imbroda B, Aragón IM, Hierro MI, Álvarez M, Alaminos M, et al. Histology and histopathology 2017 Mar;32(3):283-291
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Jul 1;28(7):1508-1516
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, et al. Lancet (London, England) 2017 Jan 21;389(10066):255-265
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, et al. European journal of endocrinology 2017 Oct;177(4):309-317
Beta-catenin and p53 expression in topographic compartments of colorectal cancer and its prognostic value following surgery
Prieto JD, Álvarez M, Hierro MI, García I, Vicioso L Annals of diagnostic pathology 2017 Dec;31():1-8
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Jun;19(6):667-681
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, et al. Oncotarget 2017 Mar 28;8(13):21472-21482
DNA Repair in Prostate Cancer: Biology and Clinical Implications
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, et al. European urology 2017 Mar;71(3):417-425
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
Pivot X, Verma S, Fallowfield L, Müller V, Lichinitser M, et al. European journal of cancer (Oxford, England : 1990) 2017 Nov;86():82-90
Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours
Sanmamed MF, Esteban E, Uriol E, Zarate R, Capelan M, et al. Journal of translational medicine 2017 Mar 20;15(1):62
Evaluation of the VeriStrat (R) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, et al. Lung cancer (Amsterdam, Netherlands) 2017 Jul;109():101-108
F-18-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
Quintela-Fandino M, Lluch A, Manso L, Calvo I, Cortes J, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Mar 15;23(6):1432-1441
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, et al. Scientific reports 2017 Jan 24;7():41371
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, et al. European journal of cancer (Oxford, England : 1990) 2017 Apr;75():73-82
Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study
Pérez-Beteta J, Martínez-González A, Molina D, Amo-Salas M, Luque B, et al. European radiology 2017 Mar;27(3):1096-1104
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
Provencio M, Sabín P, Gomez-Codina J, Torrente M, Calvo V, et al. PloS one 2017;12(5):e0177204
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Dec 1;28(12):2943-2949
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb;19(2):219-226
Malignant bone tumors (other than Ewings): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, et al. Cancer chemotherapy and pharmacology 2017 Dec;80(6):1113-1131
mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish lymphoma oncology group
Provencio M, Rodríguez M, Cantos B, Sabín P, Quero C, et al. Oncotarget 2017 Aug 1;8(31):50949-50957
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, et al. Nature 2017 Jul 6;547(7661):109-113
Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma
Álvarez R, Alés I, Díaz R, de Paredes BG, Hidalgo M Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Oct;19(10):1193-1198
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Jun;19(6):761-768
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, et al. Investigational new drugs 2017 Apr;35(2):235-241
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, et al. Neuro-oncology 2017 Oct 19;19(11):1522-1531
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Franco Pérez F, Lavernia J, Aguiar-Bujanda D, Miramón J, Gumá J, et al. Clinical lymphoma, myeloma & leukemia 2017 Mar;17(3):186-191
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Jul 1;28(7):1590-1596
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients
Gonzalez-Billalabeitia E, Castellano D, Sobrevilla N, Guma J, Hervas D, et al. Journal of the National Cancer Institute 2017 Jan;109(4):
Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for Non-Hodgkin Follicular Lymphoma Patients: A Study Report From the Spanish Lymphoma Oncology Group
Provencio M, Royuela A, Torrente M, Pollán M, Gómez-Codina J, et al. Cancer 2017 Oct 1;123(19):3709-3716
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2017 Apr;12(4):752-762
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2017 Oct 1;28(10):2464-2471
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, et al. JAMA 2017 May 9;317(18):1844-1853
The Impact of Body Mass Index and Nuclear beta-Catenin on Survival in Locally Advanced Rectal Cancer Treated With Preoperative Radiochemotherapy
Gomez-Millan J, Queipo MI, Del Mar Delgado M, Perez-Villa L, Roman A, et al. Journal of surgical oncology 2017 Mar;115(3):301-306
Acute Liver Failure Caused by Primary Non-Hodgkin’s Lymphoma of the Liver
Romacho López L, León Díaz FJ, Sánchez Pérez B, Pérez Daga JA, Fernández Aguilar JL, et al. Transplantation proceedings 2016 Nov;48(9):3000-3002
Advanced Online Survival Analysis Tool for Predictive Modelling in Clinical Data Science
Montes-Torres J, Subirats JL, Ribelles N, Urda D, Franco L, et al. PloS one 2016;11(8):e0161135
Autonomic dysfunction elicited by a medulla oblongata injury after fourth ventricle tumor surgery in a pediatric patient
Martín-Gallego A, Andrade-Andrade I, Dawid-Milner MS, Domínguez-Páez M, Romero-Moreno L, et al. Autonomic neuroscience : basic & clinical 2016 Jan;194():52-7
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, et al. European urology 2016 Dec;70(6):985-992
Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial
Cuesta-Vargas AI, Carabantes F, Caracuel Z, Conejo I, Alba E Trials 2016 Jan 5;17():8
Ethmoidal meningoencephalocele and CSF leak after posthaemorrhagic ventricular dilatation in a newborn child
González-García L, Ros-López B, Iglesias-Moroño S, Martín-Gallego Á, Carrasco-Brenes A, et al. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2016 Feb;32(2):369-75
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 Aug;18(8):805-12
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, et al. The oncologist 2016 Feb;21(2):150-5
Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients
Caba O, Irigoyen A, Jimenez-Luna C, Benavides M, Ortuño FM, et al. Toxicology and applied pharmacology 2016 Nov 15;311():113-116
Impact of Liver Graft Transport on Postoperative Results and Short-Term Liver Survival
Gámez Córdoba ME, Sánchez Pérez B, Santoyo Santoyo J, Fernández Aguilar JL, Suárez Muñoz MA, et al. Transplantation proceedings 2016 Sep;48(7):2488-2490
Micellar electrokinetic chromatographic method for the dabrafenib determination in biological samples
Rodríguez J, Castañeda G, Muñoz L, Lizcano I, Berciano MA Electrophoresis 2016 May;37(10):1296-302
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, et al. Current cancer drug targets 2016;16(5):415-28
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, et al. The Journal of endocrinology 2016 Nov;231(2):135-145
Pancreas Preservation With Viaspan, Celsior, and Custodiol Solutions: An Initial Experience
Montiel-Casado MC, Pérez-Daga JA, Blanco-Elena JA, Aranda-Narváez JM, Sánchez-Pérez B, et al. Transplantation proceedings 2016 Nov;48(9):3040-3042
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
Kong A, Rea D, Ahmed S, Beck JT, López López R, et al. Oncotarget 2016 Jun 21;7(25):37680-37692
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Reynés G, Martínez-Sales V, Vila V, Balañá C, Pérez-Segura P, et al. Anti-cancer drugs 2016 Feb;27(2):133-7
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.
Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Feb 1;22(3):560-6
Prognosis of atypical teratoid rhabdoid tumors (AT/RT) treated with multimodal therapy protocols. Report of our series
Valencia-Moya A, González-García L, Ros-López B, Acha-García T, Weil-Lara B, et al. Neurocirugia (Asturias, Spain) 2016 Mar-Apr;27(2):87-94
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Jul 1;34(19):2294-302
Recommendations in the management of epithelial appendiceal neoplasms and peritoneal dissemination from mucinous tumours (pseudomyxoma peritonei)
Barrios P, Losa F, Gonzalez-Moreno S, Rojo A, Gómez-Portilla A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 May;18(5):437-48
Results of Liver Transplantation With Donors Older than 75 Years: A Case-Control Study
León Díaz FJ, Fernández Aguilar JL, Sánchez Pérez B, Montiel Casado C, Aranda Narváez JM, et al. Transplantation proceedings 2016 Sep;48(7):2499-2502
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, et al. The New England journal of medicine 2016 Nov 3;375(18):1738-1748
Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist
Cacicedo J, Navarro A, Del Hoyo O, Gomez-Iturriaga A, Alongi F, et al. The British journal of radiology 2016 Nov;89(1067):20160217
Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study
Teixidor P, Arráez MÁ, Villalba G, Garcia R, Tardáguila M, et al. PloS one 2016;11(2):e0149244
Safety and Efficacy of Early Everolimus When Calcineurin Inhibitors Are Not Recommended in Orthotopic Liver Transplantation
Gastaca M, Bilbao I, Jimenez M, Bustamante J, Dopazo C, et al. Transplantation proceedings 2016 Sep;48(7):2506-2509
SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)
Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 Dec;18(12):1221-1228
SEOM Clinical Guideline of management of soft-tissue sarcoma (2016)
López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 Dec;18(12):1213-1220
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy
Gomez-Millan J, Pajares B, Perez-Villa L, Carnero A, Alvarez M, et al. BMC cancer 2016 Oct 28;16(1):829
Supervised discretization can discover risk groups in cancer survival analysis
Gómez I, Ribelles N, Franco L, Alba E, Jerez JM Computer methods and programs in biomedicine 2016 Nov;136():11-9
Surgical outcome of the shunt: 15-year experience in a single institution
Iglesias S, Ros B, Martín Á, Carrasco A, Segura M, et al. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2016 Dec;32(12):2377-2385
Survival analysis of surgically evacuated supratentorial spontaneous intracerebral hemorrhage with intraventricular extension
Rivera-Fernández R, Guerrero-López F, Rodríguez-Rubio D, Gómez-Jiménez FJ, Rodríguez-Vilanova F, et al. Neurocirugia (Asturias, Spain) 2016 Sep-Oct;27(5):220-8
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer
Castro E, Mateo J, Olmos D, de Bono JS Cancer journal (Sudbury, Mass.) 2016 Sep/Oct;22(5):353-356
Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival
Molina D, Pérez-Beteta J, Luque B, Arregui E, Calvo M, et al. The British journal of radiology 2016 Aug;89(1064):20160242
Up-to-7 Criteria for Hepatocellular Carcinoma Liver Transplantation: A Retrospective Analysis of Experiences
León Díaz FJ, Pérez Daga JA, Sánchez Pérez B, Fernández Aguilar JL, Montiel Casado C, et al. Transplantation proceedings 2016 Nov;48(9):2969-2972
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma
Rueda A, García-Sanz R, Pastor M, Salar A, Labrador J, et al. Acta oncologica (Stockholm, Sweden) 2015 Jun;54(6):933-8
Acute abdomen in patients with systemic lupus erythematosus and antiphospholipid syndrome. Importance of early diagnosis and treatment
Titos-García A, Aranda-Narváez JM, Marín-Camero N, Fernández-Burgos IR, Montiel-Casado MC, et al. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 2015 Jan;107(1):41-4
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, et al. The Lancet. Oncology 2015 Aug;16(8):897-907
Analysis of risk factors for hydrocephalus development in newborn infants with germinal matrix hemorrhage
Romero L, Ros B, Arráez MA, Ríus F, González L, et al. Minerva pediatrica 2015 Oct;67(5):401-6
Applicability of the da Vinci robotic system in the skull base surgical approach. Preclinical investigation
Fernandez-Nogueras Jimenez FJ, Segura Fernandez-Nogueras M, Jouma Katati M, Arraez Sanchez MÁ, Roda Murillo O, et al. Neurocirugia (Asturias, Spain) 2015 Sep-Oct;26(5):217-23
Biliary tract cancers: SEOM clinical guidelines.
Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015 Dec;17(12):982-7
Cell Therapy for Stress Urinary Incontinence
Hart ML, Izeta A, Herrera-Imbroda B, Amend B, Brinchmann JE Tissue engineering. Part B, Reviews 2015 Aug;21(4):365-76
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, et al. The oncologist 2015 May;20(5):474-82
Endoscopic endonasal resection of clival xanthoma: case report and literature review.
González-García L, Asenjo-García B, Bautista-Ojeda MD, Domínguez-Páez M, Romero-Moreno L, et al. Neurosurgical review 2015 Oct;38(4):765-9
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Nov 10;33(32):3788-95
Estimating Preferences for Treatments in Patients With Localized Prostate Cancer
Ávila M, Becerra V, Guedea F, Suárez JF, Fernandez P, et al. International journal of radiation oncology, biology, physics 2015 Feb 1;91(2):277-87
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, et al. BMC cancer 2015 Jul 4;15():495
Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain
Expósito J, Linares I, Castillo I, Martínez M, Vargas P, et al. Radiation oncology (London, England) 2015 Dec 30;10():265
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours
Sastre J, Massuti B, Pulido G, Guillén-Ponce C, Benavides M, et al. European journal of cancer (Oxford, England : 1990) 2015 Jul;51(11):1371-80
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, et al. Cancer metastasis reviews 2015 Dec;34(4):823-42
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel
Arriola E, Reguart N, Artal A, Cobo M, García-Campelo R, et al. Future oncology (London, England) 2015;11(2):267-77
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)(aEuro)
Grande E, Capdevila J, Castellano D, Teulé A, Durán I, et al. Annals of oncology : official journal of the European Society for Medical Oncology 2015 Sep;26(9):1987-1993
Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer
Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y, Santonja A, Moreno I, et al. Clinical breast cancer 2015 Oct;15(5):343-7
Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
de Castro J, Cobo M, Isla D, Puente J, Reguart N, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015 Jan;17(1):11-23
Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus
Rovirosa Á, Anchuelo J, Crispin V, Gutiérrez C, Herreros A, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2015 Aug;17(8):581-9
Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)
Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, et al. Annals of surgical oncology 2015 Sep;22(9):2948-57
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma
Rueda A, Olmos D, Vicioso L, Quero C, Gallego E, et al. Leukemia & lymphoma 2015 May;56(5):1286-94
Stress urinary incontinence animal models as a tool to study cell-based regenerative therapies targeting the urethral sphincter
Herrera-Imbroda B, Lara MF, Izeta A, Sievert KD, Hart ML Advanced drug delivery reviews 2015 Mar;82-83():106-16
Testicular epidermoid cyst: A rare entity
Sáez Barranquero F, Regaña Feijoo MJ, Del Río González S, García Del Pino MJ, Cantero Mellado JA, et al. Archivos espanoles de urologia 2015 Oct;68(8):672-5
Enlaces
Calle Severo Ochoa, 35
Parque Tecnol?gico de Andaluc?a (PTA) Campanillas,
M?laga 29590
(+34) 951 440 260
Fax: (+34) 951 440 263